China’s Grit Biotechnology raises $60m in Series B to develop TIL portfolio
The financing is expected to drive Grit Biotechnology’s Phase 2 trial for GT101 and further development of next-generation…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
11 Sep 23
The financing is expected to drive Grit Biotechnology’s Phase 2 trial for GT101 and further development of next-generation…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Sep 23
The MAA is backed by findings from Cohort 1 of the randomised, controlled, open-label, multicentre Phase 3 THOR…
11 Sep 23
Under the deal, Nurix will receive an upfront payment of $60m along with the potential to get research,…
11 Sep 23
The collaboration aims to introduce digital medicine research solutions that harness the power of artificial intelligence (AI) to…
11 Sep 23
Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased…
11 Sep 23
Resubmission to FDA planned for early 2024
11 Sep 23
The iconic cheese brand is encouraging fans to nominate the funniest person in their life to win a…
11 Sep 23
Plan Marks Key Step in Merger Process
11 Sep 23
BioGX, a global provider of molecular diagnostic solutions, announces the availability of three new Xfree™ Direct-Sample-to-Answer PCR multiplexes…
11 Sep 23
Cheetos lovers can celebrate with Cheetle-inspired, limited-edition merch straight from the runway along with Milk Bar's Cheetle-infused Birthday…